FLT1 rs7993418: Understanding This Genetic Variant

What each genotype means

What is the rs7993418 Variant?

The rs7993418 variant is a single nucleotide polymorphism (SNP) located within the FLT1 gene. In genetics, a SNP represents a variation at a single position in the DNA sequence. This specific variant is categorized as a coding variant, meaning it occurs in a region of the gene that provides instructions for building a protein. Specifically, rs7993418 is associated with changes in codon usage, which can influence how the cell translates genetic information into the final protein structure. Because this variant sits within the coding sequence of the FLT1 gene, researchers have studied whether it alters the expression levels or functional efficiency of the resulting receptor. Understanding such variants is a key focus of pharmacogenomics, the study of how an individual's genetic makeup influences their response to medications.

The Role of the FLT1 Gene

The FLT1 gene provides instructions for making a protein called vascular endothelial growth factor receptor 1, commonly known as VEGFR1. This protein is a member of the receptor tyrosine kinase family, which acts as a critical signaling hub on the surface of cells. VEGFR1 plays a pivotal role in angiogenesis, the biological process through which new blood vessels form from pre-existing ones. By binding to vascular endothelial growth factors, the receptor helps regulate endothelial cell function, vascular development, and inflammation. Because angiogenesis is essential for both healthy tissue maintenance and the growth of certain tumors, the VEGFR1 receptor is a significant target in medical research. Variations in the FLT1 gene, such as rs7993418, are of interest because they may theoretically impact the sensitivity or activity of this signaling pathway.

Research and Clinical Associations

Scientific research into rs7993418 has primarily focused on its potential as a biomarker in oncology and pharmacogenomics. Some studies have explored whether this variant influences progression-free survival in patients undergoing anti-angiogenic therapy, such as bevacizumab. For instance, research in specific cancer cohorts, including gastric cancer, has examined whether certain genotypes of rs7993418 correlate with different patterns of disease progression or metastasis. However, it is important to note that the evidence strength for these associations remains limited. Findings are often derived from retrospective studies, and results can vary significantly between different patient populations and disease types. Because the evidence is not yet robust enough to guide standard clinical practice, this variant is currently considered a subject of ongoing investigation rather than a definitive diagnostic tool.

Population Frequency and Interpretation

The rs7993418 variant is considered common on a global scale. Data indicates that the minor allele frequency typically ranges between 0.40 and 0.50 in both European and Asian populations. This high frequency suggests that a large portion of the general population carries at least one copy of the variant allele. When interpreting such information, it is crucial to remember that having a common genetic variant does not equate to having a disease or a guaranteed response to a specific medication. Genetic associations are statistical in nature, describing trends observed in large groups rather than predicting individual outcomes. If you are concerned about how your genetic profile might influence your medical treatment, the most appropriate step is to discuss your specific clinical situation with your healthcare provider or a pharmacist, who can provide guidance based on your full medical history.

Frequently asked questions

Sources & further reading

Related variants in FLT1